Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
SCPH logo SCPH
Upturn stock ratingUpturn stock rating
SCPH logo

Scpharmaceuticals Inc (SCPH)

Upturn stock ratingUpturn stock rating
$5.51
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/28/2025: SCPH (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

6 Analysts rated it

Limited analyst coverage, niche firm, research info may be scarce.

1 Year Target Price $15.5

1 Year Target Price $15.5

Analysts Price Target For last 52 week
$15.5 Target price
52w Low $1.94
Current$5.51
52w High $6.28

Analysis of Past Performance

Type Stock
Historic Profit 3.03%
Avg. Invested days 30
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/28/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 295.23M USD
Price to earnings Ratio -
1Y Target Price 15.5
Price to earnings Ratio -
1Y Target Price 15.5
Volume (30-day avg) 6
Beta 0.39
52 Weeks Range 1.94 - 6.28
Updated Date 08/29/2025
52 Weeks Range 1.94 - 6.28
Updated Date 08/29/2025
Dividends yield (FY) -
Basic EPS (TTM) -1.81

Earnings Date

Report Date 2025-08-07
When -
Estimate -0.29
Actual -0.34

Profitability

Profit Margin -183.55%
Operating Margin (TTM) -89.11%

Management Effectiveness

Return on Assets (TTM) -57.08%
Return on Equity (TTM) -934.02%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 307409171
Price to Sales(TTM) 5.91
Enterprise Value 307409171
Price to Sales(TTM) 5.91
Enterprise Value to Revenue 6.15
Enterprise Value to EBITDA -6.69
Shares Outstanding 53678800
Shares Floating 32536478
Shares Outstanding 53678800
Shares Floating 32536478
Percent Insiders 5.98
Percent Institutions 75.72

ai summary icon Upturn AI SWOT

Scpharmaceuticals Inc

stock logo

Company Overview

overview logo History and Background

scPharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing products that have the potential to transform the way serious diseases are treated, primarily in the acute care setting. Founded in 2013, scPharmaceuticals aims to reduce healthcare costs and improve patient outcomes through subcutaneous delivery systems.

business area logo Core Business Areas

  • FUROSCIX: FUROSCIX is scPharmaceuticals' lead product, a proprietary, preservative-free formulation of furosemide for subcutaneous administration for the treatment of congestion due to heart failure. It is designed to provide consistent and predictable diuresis compared to IV furosemide, with potential for at-home administration.

leadership logo Leadership and Structure

The company's leadership team includes individuals with experience in pharmaceutical development, regulatory affairs, and commercialization. The organizational structure is typical of a biotech company, with departments focused on research and development, clinical trials, manufacturing, and commercial operations.

Top Products and Market Share

overview logo Key Offerings

  • FUROSCIX: FUROSCIX (furosemide injection) for subcutaneous use is indicated for the treatment of congestion due to fluid overload in adults with New York Heart Association (NYHA) Class II and III heart failure. Market share is emerging after commercial launch in early 2023. Competitors include oral furosemide and IV furosemide. There is not a direct competitor offering subcutaneous furosemide. scPharmaceuticals holds a unique market position.

Market Dynamics

industry overview logo Industry Overview

The biopharmaceutical industry is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. The heart failure market is significant and growing due to an aging population and increasing prevalence of chronic diseases.

Positioning

scPharmaceuticals is positioned as an innovator in the treatment of heart failure, offering a novel subcutaneous delivery option. The company aims to capture a portion of the market currently served by IV and oral diuretics.

Total Addressable Market (TAM)

The total addressable market for heart failure treatments is substantial, estimated at billions of dollars annually. scPharmaceuticals is positioned to capture a portion of this TAM by offering a convenient and potentially cost-effective alternative to existing therapies. Exact figures for subcutaneous diuresis are unavailable but IV diuresis spends multiple billions, representing the available TAM opportunity for SC formulation.

Upturn SWOT Analysis

Strengths

  • Novel subcutaneous delivery system
  • Potential for at-home administration
  • Improved patient convenience
  • Strong intellectual property protection
  • Addresses a significant unmet need in heart failure management

Weaknesses

  • Reliance on a single product (FUROSCIX)
  • Dependence on successful commercialization
  • Requires physician and patient adoption of new technology
  • Limited operating history
  • Relatively small company size

Opportunities

  • Expansion of indications for FUROSCIX
  • Development of new subcutaneous drug delivery platforms
  • Strategic partnerships with pharmaceutical companies
  • Market growth in heart failure treatments
  • Potential for international expansion

Threats

  • Competition from existing diuretics and other heart failure therapies
  • Regulatory hurdles and delays
  • Pricing and reimbursement pressures
  • Adverse events or safety concerns
  • Generic entry if patents are not properly enforced

Competitors and Market Share

competitor logo Key Competitors

  • LLY
  • NVS
  • VTRS

Competitive Landscape

scPharmaceuticals' advantage lies in its novel subcutaneous delivery system, which differentiates it from traditional diuretics. However, it faces competition from established pharmaceutical companies with greater resources and broader product portfolios.

Growth Trajectory and Initiatives

Historical Growth: Historical growth is limited due to the recent commercial launch of FUROSCIX.

Future Projections: Future growth is dependent on the successful adoption of FUROSCIX and potential expansion into new markets.

Recent Initiatives: Recent initiatives include expanding the sales force, conducting post-marketing studies, and pursuing regulatory approvals in additional countries.

Summary

scPharmaceuticals is a small company with a promising, novel drug delivery system for heart failure. However, it is early in its commercial trajectory and faces several risks related to market adoption, competition, and regulatory hurdles. FUROSCIX offers advantages over traditional methods, but it must successfully gain trust among physicians and patients. The company's long-term success hinges on securing reimbursement coverage and broadening their market presence.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • scPharmaceuticals Investor Relations
  • SEC Filings
  • Industry Reports

Disclaimers:

The information provided is for informational purposes only and does not constitute financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Scpharmaceuticals Inc

Exchange NASDAQ
Headquaters Burlington, MA, United States
IPO Launch date 2017-11-17
President, CEO, Principal Executive Officer & Director Mr. John H. Tucker
Sector Healthcare
Industry Biotechnology
Full time employees 162
Full time employees 162

scPharmaceuticals Inc., a pharmaceutical company, focuses on developing and commercializing products to optimize the delivery of infused therapies and patient care. The company's lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for the treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX. Its product pipeline also includes SCP-111 (furosemide injection), an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home; and SCP-111 Autoinjector, an investigational single-entity and drug-device combination product candidate consisting of a prefilled syringe containing SCP-111 preloaded into a mechanical autoinjector. The company was incorporated in 2013 and is headquartered in Burlington, Massachusetts.